Historical dataset showing Japan infant mortality rate by year from 1950 to 2025.

Actual value and historical data chart for Japan Mortality Rate Infant Male Per 1000 Live Births

This statistic shows the 20 countries * with the lowest infant mortality rate in 2024. An estimated 1.5 out of 1,000 live births died in the first year of life in Slovenia and Singapore in 2024. Infant mortality Infant mortality rates are often used as an indicator of the health and well-being of a nation. Monaco, Iceland, and Japan are among the top three countries with the lowest infant mortality rates with around 2 infant deaths per 1,000 infants within their first year of life. Generally, the countries with the lowest infant mortality also have some of the highest average life expectancy figures. Additionally, the countries with the highest density of physicians and doctors also generally report low infant mortality. Yet, many different factors contribute to differing rates, including the overall income of a country, health spending per capita, a mother’s level of education, environmental conditions, and medical infrastructure, to name a few. This creates a lot of variation concerning the level of childbirth and infant care around the world. The countries with the highest rates of infant mortality include Afghanistan, Mali, and Somalia. These countries experience around 100 infant deaths per 1,000 infants in their first year of life. While the reasons for high rates of infant mortality are numerous, the leading causes of death for children under the year five around the world are Pneumonia, Diarrhea, and Prematurity.

Number of infant deaths in Japan was reported at 1359 deaths in 2023, according to the World Bank collection of development indicators, compiled from officially recognized sources. Japan - Number of infant deaths - actual values, historical data, forecasts and projections were sourced from the World Bank on October of 2025.

Infant Non-Contact Respiration Radar Monitors Market Outlook

According to our latest research, the Global Infant Non-Contact Respiration Radar Monitors market size was valued at $425 million in 2024 and is projected to reach $1.12 billion by 2033, expanding at a robust CAGR of 11.2% during the forecast period of 2025–2033. The primary driver fueling this remarkable growth is the rising demand for advanced, non-invasive monitoring solutions for infants, particularly in neonatal intensive care units (NICUs) and home care settings. With increasing awareness among parents and healthcare professionals regarding the risk of Sudden Infant Death Syndrome (SIDS) and respiratory complications in newborns, the adoption of non-contact radar-based monitors is rapidly accelerating. These devices offer continuous, real-time respiratory monitoring without physical attachment, thereby reducing the risk of skin irritation and infection, and providing peace of mind to caregivers and clinicians alike.

Regional Outlook

North America currently commands the largest share of the Infant Non-Contact Respiration Radar Monitors market, accounting for nearly 38% of the global revenue in 2024. This dominance is attributed to the region’s well-established healthcare infrastructure, high awareness levels regarding infant health and safety, and a strong presence of leading medical device manufacturers. The United States, in particular, benefits from favorable reimbursement policies and a proactive regulatory environment that encourages innovation and rapid adoption of advanced healthcare technologies. The prevalence of technologically advanced hospitals and the growing trend of home healthcare further bolster the market’s performance in North America. Additionally, the region’s robust investment in research and development, coupled with frequent product launches, has solidified its leadership position in the global market.

Asia Pacific stands out as the fastest-growing region in the Infant Non-Contact Respiration Radar Monitors market, projected to expand at an impressive CAGR of 14.5% from 2025 to 2033. The surge in demand is driven by rapidly improving healthcare infrastructure, increasing birth rates, and heightened awareness of infant safety among the burgeoning middle-class population. Countries such as China, India, and Japan are witnessing significant investments in neonatal care, fueled by government initiatives and public-private partnerships aimed at reducing infant mortality rates. The proliferation of smart hospitals and the adoption of digital healthcare solutions are further accelerating market growth in the region. Moreover, local manufacturers are increasingly collaborating with global players to introduce cost-effective, technologically advanced monitoring devices tailored to regional needs.

Emerging economies in Latin America, the Middle East, and Africa are demonstrating increasing interest in Infant Non-Contact Respiration Radar Monitors, though market penetration remains in its nascent stages. Adoption is often hampered by challenges such as limited healthcare budgets, lack of awareness, and inadequate distribution networks. However, localized demand is gradually rising, particularly in urban centers where private healthcare providers are seeking to differentiate themselves through advanced neonatal care offerings. Policy reforms and international aid programs are beginning to improve access to modern medical devices, but substantial growth will depend on overcoming regulatory hurdles and addressing affordability concerns. As global manufacturers expand their reach and local governments prioritize infant health, these regions are expected to play a more prominent role in the market’s long-term expansion.

Report Scope

Noninvasive Bilirubin Forehead Sensors Market Outlook

According to our latest research, the Global Noninvasive Bilirubin Forehead Sensors market size was valued at $325 million in 2024 and is projected to reach $678 million by 2033, expanding at a robust CAGR of 8.4% during the forecast period of 2025–2033. The primary factor propelling the growth of this market globally is the increasing prevalence of neonatal jaundice, which demands efficient, accurate, and noninvasive diagnostic solutions. The shift towards noninvasive technologies in healthcare, particularly for vulnerable populations such as newborns, is further accelerating the adoption of these sensors. In addition, advancements in sensor technology and the growing emphasis on point-of-care diagnostics are expected to drive market expansion in the coming years.

Regional Outlook

North America currently commands the largest share of the Noninvasive Bilirubin Forehead Sensors market, accounting for approximately 37% of global revenue in 2024. This dominance is largely attributed to the region’s mature healthcare infrastructure, high awareness levels among healthcare professionals, and the presence of leading medical device manufacturers. The United States, in particular, benefits from favorable reimbursement policies, widespread neonatal screening programs, and a strong focus on early disease detection. The region’s proactive regulatory environment and rapid adoption of innovative medical technologies have fostered an ecosystem where noninvasive bilirubin sensors are widely utilized in hospitals, clinics, and even homecare settings. Furthermore, ongoing investments in research and development, along with strategic collaborations between healthcare providers and technology companies, further solidify North America’s leadership position in this market.

The Asia Pacific region is emerging as the fastest-growing market, projected to register a remarkable CAGR of 10.6% from 2025 to 2033. This impressive growth trajectory is fueled by increasing birth rates, rising incidences of neonatal jaundice, and expanding healthcare infrastructure in countries such as China, India, and Japan. Government initiatives aimed at reducing infant mortality rates and improving maternal and child health are driving the adoption of advanced diagnostic technologies, including noninvasive bilirubin forehead sensors. Additionally, the region is witnessing significant investments from both domestic and international players, who are keen to tap into the vast unmet medical needs and rapidly growing middle-class population. The proliferation of private healthcare facilities and the increasing focus on affordable, accessible diagnostics are expected to further boost market expansion in Asia Pacific.

In contrast, emerging economies in Latin America and the Middle East & Africa present a mixed outlook for the Noninvasive Bilirubin Forehead Sensors market. While these regions are gradually embracing noninvasive diagnostic technologies, several challenges persist, including limited healthcare budgets, insufficient infrastructure, and a lack of trained personnel. However, localized demand is steadily increasing, driven by rising awareness of neonatal health issues and the efforts of non-governmental organizations to improve healthcare outcomes. Policy reforms and international aid programs are beginning to enhance access to modern medical devices, but the pace of adoption remains slower compared to more developed regions. Over the forecast period, targeted investments and government-led initiatives could help bridge the gap and unlock new growth opportunities in these emerging markets.

Report Scope

Connected Neonatal Incubator Market Outlook

According to our latest research, the Global Connected Neonatal Incubator market size was valued at $1.3 billion in 2024 and is projected to reach $2.7 billion by 2033, expanding at a robust CAGR of 8.4% during the forecast period of 2025–2033. One of the major factors driving the remarkable growth of this market globally is the increasing emphasis on advanced neonatal care, particularly the integration of smart technologies for real-time monitoring and improved outcomes for premature and critically ill infants. The surge in preterm births, coupled with the rising adoption of digital health solutions across healthcare institutions, is compelling providers to invest in connected neonatal incubators that offer enhanced safety, remote monitoring, and data-driven decision-making capabilities.

Regional Outlook

North America continues to dominate the Connected Neonatal Incubator market, accounting for the largest share of global revenue, estimated at over 38% in 2024. This leadership can be attributed to the region’s mature healthcare infrastructure, high adoption rate of cutting-edge medical technologies, and supportive government policies that incentivize the implementation of advanced neonatal care solutions. The presence of leading manufacturers, strong research and development pipelines, and robust reimbursement frameworks further fuel market growth in the United States and Canada. In addition, the region benefits from stringent regulatory standards that ensure product quality and safety, thereby fostering trust and widespread deployment of connected neonatal incubators in both public and private healthcare settings.

The Asia Pacific region is emerging as the fastest-growing market for connected neonatal incubators, with a projected CAGR exceeding 10.2% from 2025 to 2033. This rapid expansion is driven by significant investments in healthcare infrastructure, particularly in countries such as China, India, and Japan. The growing awareness of neonatal health, rising birth rates, and increasing prevalence of premature births are spurring demand for technologically advanced incubators. Government initiatives aimed at reducing infant mortality rates and improving maternal-child health services have led to greater budget allocations and public-private partnerships. As a result, hospitals and specialty clinics across Asia Pacific are accelerating the adoption of wireless, integrated neonatal incubators to enhance care quality and streamline operations.

Emerging economies in Latin America, the Middle East, and Africa are witnessing gradual but promising adoption of connected neonatal incubators. However, these regions face unique challenges such as limited healthcare budgets, inadequate infrastructure, and a shortage of skilled healthcare professionals. Despite these obstacles, localized demand is rising due to increasing awareness about neonatal care and the gradual rollout of government-supported healthcare reforms. Policy initiatives focused on improving maternal and child health, along with international aid and non-governmental funding, are expected to gradually bridge the adoption gap. Nevertheless, the pace of market penetration remains slower compared to North America and Asia Pacific, highlighting the need for tailored solutions and capacity-building efforts.

Report Scope

Lacto-N-fucopentaose II Market Outlook

According to our latest research, the Lacto-N-fucopentaose II market size was valued at $98 million in 2024 and is projected to reach $315 million by 2033, expanding at a robust CAGR of 13.7% during the forecast period of 2025–2033. One of the principal factors underpinning this substantial growth is the surging demand for advanced infant nutrition products that closely mimic the composition of human breast milk. Lacto-N-fucopentaose II, a human milk oligosaccharide (HMO), is increasingly being recognized for its role in supporting infant gut health, immunity, and cognitive development, driving its integration into infant formula and functional foods worldwide. As consumer awareness of early-life nutrition grows and scientific research into HMOs expands, the market for Lacto-N-fucopentaose II is poised for significant global expansion.

Regional Outlook

North America currently commands the largest share of the global Lacto-N-fucopentaose II market, accounting for approximately 38% of total revenue in 2024. This dominance is attributed to the region’s mature infant formula industry, high consumer awareness regarding the benefits of HMOs, and a favorable regulatory environment that encourages innovation in functional ingredients. The United States, in particular, has seen rapid adoption of Lacto-N-fucopentaose II in premium infant formulas and dietary supplements, driven by leading market players and robust research and development activities. Furthermore, strong collaborations between academic institutions and commercial entities have accelerated product approvals and market penetration, cementing North America’s leadership position in this sector.

Asia Pacific is emerging as the fastest-growing region in the Lacto-N-fucopentaose II market, projected to register a CAGR of 16.2% from 2025 to 2033. This impressive growth is fueled by rising birth rates, increasing disposable incomes, and heightened awareness of infant health and nutrition across countries such as China, Japan, and India. The expanding middle class and urbanization trends have led to greater demand for premium and specialized infant formulas fortified with HMOs like Lacto-N-fucopentaose II. Additionally, significant investments by both multinational and local companies in R&D and manufacturing capabilities are accelerating product launches and distribution networks, making Asia Pacific a key growth engine for the global market.

In emerging economies across Latin America and the Middle East & Africa, the adoption of Lacto-N-fucopentaose II remains in the nascent stages, primarily due to limited awareness, cost constraints, and regulatory complexities. However, these regions present considerable long-term potential as governments and health organizations intensify efforts to improve early-life nutrition and reduce infant mortality rates. Localized demand is gradually increasing, especially as multinational players expand their footprint and tailor products to regional preferences. Nevertheless, challenges such as underdeveloped distribution channels, inconsistent regulatory standards, and affordability issues continue to restrain rapid market expansion in these geographies.

Report Scope

In 2025, India overtook China as the world's most populous country and now has almost 1.46 billion people. China now has the second-largest population in the world, still with just over 1.4 billion inhabitants, however, its population went into decline in 2023. Global population As of 2025, the world's population stands at almost 8.2 billion people and is expected to reach around 10.3 billion people in the 2080s, when it will then go into decline. Due to improved healthcare, sanitation, and general living conditions, the global population continues to increase; mortality rates (particularly among infants and children) are decreasing and the median age of the world population has steadily increased for decades. As for the average life expectancy in industrial and developing countries, the gap has narrowed significantly since the mid-20th century. Asia is the most populous continent on Earth; 11 of the 20 largest countries are located there. It leads the ranking of the global population by continent by far, reporting four times as many inhabitants as Africa. The Demographic Transition The population explosion over the past two centuries is part of a phenomenon known as the demographic transition. Simply put, this transition results from a drastic reduction in mortality, which then leads to a reduction in fertility, and increase in life expectancy; this interim period where death rates are low and birth rates are high is where this population explosion occurs, and population growth can remain high as the population ages. In today's most-developed countries, the transition generally began with industrialization in the 1800s, and growth has now stabilized as birth and mortality rates have re-balanced. Across less-developed countries, the stage of this transition varies; for example, China is at a later stage than India, which accounts for the change in which country is more populous - understanding the demographic transition can help understand the reason why China's population is now going into decline. The least-developed region is Sub-Saharan Africa, where fertility rates remain close to pre-industrial levels in some countries. As these countries transition, they will undergo significant rates of population growth.